Vogiatzoglou Anastasios I, Hadji Μitrova Maria, Papadaki Eleni, Sionidou Maria, Nikopoulou Anna, Kontos Fanοurios, Papaventsis Dimitrios, Papavasileiou Apostolos, Manika Katerina
Pulmonology and Tuberculosis Department, General Hospital of Thessaloniki "Georgios Papanikolaou", Aristotle University of Thessaloniki, Thessaloniki, GRC.
Internal Medicine Department, General Hospital of Thessaloniki "Georgios Papanikolaou", Thessaloniki, GRC.
Cureus. 2024 Jul 22;16(7):e65112. doi: 10.7759/cureus.65112. eCollection 2024 Jul.
is a difficult-to-treat, multidrug-resistant human pathogen. Relebactam has been shown to inhibit β-lactamase (BLA) and increase the activity of imipenem and amoxicillin. We present two cases of lung infection due to , one caused by subsp and the other by subsp. Both strains showed moderate sensitivity to imipenem, and the second strain was also resistant to macrolides. A multidrug antibiotic regimen was administered in both cases, which included imipenem/cilastatin/relebactam adjusted to the estimated glomerular filtration rate (eGFR) and amoxicillin for three months. The regimen was well tolerated and both patients improved both clinically and radiologically after the first phase of treatment. The results of our patients indicate that the combination of imipenem/cilastatin/relebactam and amoxicillin could be used in the future in difficult infections by .
是一种难以治疗的多重耐药人类病原体。瑞来巴坦已被证明可抑制β-内酰胺酶（BLA）并增强亚胺培南和阿莫西林的活性。我们报告了两例由引起的肺部感染病例，一例由亚种引起，另一例由亚种引起。两株菌株对亚胺培南均表现出中度敏感性，第二株菌株对大环内酯类也耐药。两例均采用了多药抗生素方案，其中包括根据估计肾小球滤过率（eGFR）调整的亚胺培南/西司他丁/瑞来巴坦和阿莫西林，疗程为三个月。该方案耐受性良好，两名患者在治疗的第一阶段后临床和影像学均有改善。我们患者的结果表明，亚胺培南/西司他丁/瑞来巴坦和阿莫西林的联合用药未来可用于由引起的难治性感染。
